Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.50 |
| ▸ | XDH | P47989 | 3/20 | 0.45 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14200028 | 0.91 | MAOB (0.56) | MAOBFNTAFNTBPGGT1BXDH | |
| SCHEMBL14200042 | 0.82 | KEAP1 (0.53) | — | |
| SCHEMBL19431639 | 0.82 | L3MBTL1 (0.48) | MAOBFNTAFNTBPGGT1BXDH | |
| SCHEMBL682767 | 0.82 | MAPT (0.49) | — | |
| SCHEMBL15831939 | 0.81 | MAOB (0.56) | MAOBFNTAFNTBPGGT1BXDH | |
| SCHEMBL18119749 | 0.80 | ACHE (0.43) | XDH | |
| SCHEMBL20766376 | 0.80 | MAOB (0.59) | MAOBFNTAFNTBPGGT1B | |
| SCHEMBL3865512 | 0.79 | MAOB (0.77) | MAOBFNTAFNTBPGGT1BXDH | |
| SCHEMBL28185508 | 0.79 | MAOB (0.58) | MAOBFNTAFNTBPGGT1BXDH | |
| SCHEMBL2700393 | 0.78 | MAOB (0.56) | MAOBFNTAFNTBPGGT1BXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | MAOB 4153/4885FNTA 4374/4885FNTB 2812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.